Longeveron Inc. (LGVN) NASDAQ
1.16
+0.05(+4.50%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.16
+0.05(+4.50%)
Currency In USD
| Previous Close | 1.11 |
| Open | 1.17 |
| Day High | 1.18 |
| Day Low | 1.09 |
| 52-Week High | 1.83 |
| 52-Week Low | 0.48 |
| Volume | 786,757 |
| Average Volume | 5.5M |
| Market Cap | 27.03M |
| PE | -0.9 |
| EPS | -1.29 |
| Moving Average 50 Days | 0.75 |
| Moving Average 200 Days | 0.84 |
| Change | 0.05 |
Longeveron Announces Closing of Private Placement of up to $30 Million
GlobeNewswire Inc.
Mar 11, 2026 8:05 PM GMT
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastl
Longeveron Announces Private Placement of up to $30 Million
GlobeNewswire Inc.
Mar 10, 2026 1:00 PM GMT
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastl
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
GlobeNewswire Inc.
Feb 25, 2026 4:05 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerativ